Chronic Kidney Disease (CKD) associated with Type 2 Diabetes

According to the Indonesia Renal Registry 2020, Chronic Kidney Disease in Type 2 Diabetes is the second most common cause of kidney failure in Indonesia, accounting for 29%.3 CKD associated with Type 2 Diabetes has a significant impact on patients' quality of life, causing disruptive symptoms, longer hospital stays, and lower survival rates compared to patients without diabetes⁴.

Patients with Chronic Kidney Disease and Type 2 Diabetes have a shorter life expectancy of up to 16 years on average⁵ and are three times more likely to die from cardiovascular-related causes compared to patients with Type 2 Diabetes alone1. Despite the use of various standard hemodynamic and metabolic therapies, patients with CKD and Type 2 Diabetes remain at high risk of CKD progression^6,7.

The FIDELIO-DKD study showed that the administration of the non-steroidal mineralocorticoid receptor antagonist (Finerenone) along with standard hemodynamic and metabolic control therapy can significantly slow down kidney damage in patients with type 2 diabetes. Finerenone can reduce the albumin-creatinine ratio (ACR) by 31% within 4 months of use. Finerenone can also reduce the risk of cardiovascular events in patients with chronic kidney disease and type 2 diabetes.⁸"

^References

<sup>1.  Afkarian M., et al. J Am Soc Nephrol. 2013;24:302–308. 
2. Bakris L., et al. NEJM 2020 3;383:2219-2229.  
3. Afiatin. 2020. Indonesia Renal Registry. Kemenkes
4. Chen L., et al. Health Qual Life Outcomes. 2020;18:266.
5. Wen C.P., et al. Kidney Int. 2017;92:388–396. 
6. Brenner B.M., et al. N Engl J Med. 2001;345:861–869.
7. Lewis E.J., et al. N Engl J Med. 2001;345:851–860
8. Bakris GL, et al. N Engl J Med 2020;383:2219–2229</sup>
 

^{Advice for patients : Each body reacts differently to medicines. Therefore, it is impossible to tell which medicine works best for you. Please consult your physician.}
 

^{COR-GEN-ID-0005-1}